Soligenix, Inc. (SNGX)

Market Cap	4.44M
Revenue (ttm)	2,342
Net Income (ttm)	-9.59M
Shares Out	3.26M
EPS (ttm)	-4.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	246,467
Open	1.370
Previous Close	1.360
Day's Range	1.340 - 1.390
52-Week Range	1.090 - 7.199
Beta	1.88
Analysts	Strong Buy
Price Target	6.00 (+341.18%)
Earnings Date	Aug 8, 2025

About SNGX

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflam...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 15, 1987
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: SNGX
• Website: https://www.soligenix.com

Financial Performance

In 2024, Soligenix's revenue was $119,371, a decrease of -85.78% compared to the previous year's $839,359. Losses were -$8.27 million, 34.6% more than in 2023.

Analyst Summary

According to one analyst, the rating for SNGX stock is "Strong Buy" and the 12-month stock price target is $6.0.

Price Target

$6.0

(341.18% upside)

Analyst Consensus: Strong Buy